(Q96230236)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

title

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Sebastian Birndt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Paul La Rosée

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

H C Bremer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

I Gehrke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Kehr

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Hochhaus

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

M Fellhauer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

M Henkes

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

B Kumle

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

S G Russo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32518419%20AND%20SRC:MED&resulttype=core&format=json

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Compassionate Use of Remdesivir for Patients with Severe Covid-19

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Inflammation and myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Virological assessment of hospitalized patients with COVID-2019

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

COVID-19: consider cytokine storm syndromes and immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Cytokine release syndrome in severe COVID-19

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Covid-19 in Critically Ill Patients in the Seattle Region - Case Series

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

A journey through infectious risk associated with ruxolitinib

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Clinical and immunological features of severe and moderate coronavirus disease 2019

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Effective treatment of severe COVID-19 patients with tocilizumab

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021

Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0891-0

7 January 2021